Nutraband Inc. Warrant (NTRBW) provides an exceptional investment vehicle linked to Nutriband Inc., an innovative biotechnology firm dedicated to developing advanced transdermal drug delivery systems that address critical healthcare challenges, particularly in pain management and addiction treatment. The company is distinguished by its proprietary technologies and a strong product pipeline poised for substantial market impact. With a strategic focus on leveraging growth opportunities within the pharmaceutical sector, Nutriband presents an appealing proposition for institutional investors seeking to capitalize on advancements in biotechnology and healthcare innovation.
| Revenue (TTM) | $1.62M |
| Gross Profit (TTM) | 536,120 |
| EBITDA | $-6.90M |
| Operating Margin | -203.60% |
| Return on Equity | -100.80% |
| Return on Assets | -53.50% |
| Revenue/Share (TTM) | $0.13 |
| Book Value | $0.44 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -29.70% |
| Shares Outstanding | 0 |
| Float | $5.28M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Volatility is currently contracting
ORLANDO, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) confirmed today that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026 at 5PM ET as scheduled.
ORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th.
Nutriband has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system. Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval.
ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit on Aug 26th as part of the CEO spotlight event.
Nutriband's Active Intelligence subsidiary to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference Company to Meet with Buyers from Walmart Inc, Walgreens, Amazon.com, Inc., Cardinal Health and Other Major National Retailers ORLANDO, Fla., May 15, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) and its wholly owned subsidiary Active Intelligence (“Active Intelligence” or the “Company”), an emerging leader in innovative wellness, recovery, and performance-focused consumer products, today announced its participation in the upcoming ECRM conference taking place in June 2026, where the Company will showcase its latest AI-branded product portfolio to buyers and executives from some of the nation's largest retail and healthcare organizations.
ORLANDO, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan has featured on the latest episode of the Jack Neel Podcast to discuss the opioid crisis, the Company's AVERSA technology and the opportunity for Nutriband to improve the safety profile of easily abused medications.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NTRBW and any ticker you trade — then tracks every position and per-strategy win rate.
